Table 1.

Baseline Characteristics of Patients Diagnosed With Pancreatic Adenocarcinoma

Characteristics	n = 180	Percentage
Gender
Male	105	58
Female	75	42
Age, year (mean, range)
≤60	52 (34–60)	29
>60	128 (61–91)	71
Ethnic origin
Caucasian	138	77
Asian	17	9
African-American	13	7
Hispanic	12	7
Year diagnosed
2009–2011	87	48
2012–2014	93	52
Pancreatic primary tumor location
Head	89	49
Body	41	23
Tail	33	18
Overlap (body and tail)	17	9
Surgery performed	n = 39	22
Whipple procedure	23	13
Other type of resectiona	11	6
Exploratory laparotomy but not resected8	5	3
AJCC stage at cancer diagnosis
I A + B	3	2
II A	17	9
II B	19	11
III	38	21
IV	103	57
CA 19-9 level at diagnosisb (range)	1–252,427
ULN to <59,000	147	82
>59 × ULN	4	2
Not available	29	16
Metastasis at diagnosis by organ site	n = 108	60
Liver only	39	22
Liver and other organs	77	43
Abdomen/peritoneum	23	13
Lung and other organs	6	3
Other (bone)	2	1
First systemic chemotherapy received	n = 169	94
Gemcitabine regimen	91	51
Gemcitabine monotherapy	28	16
Gemcitabine + oxaliplatin/cisplatin	23	13
Gemcitabine + Nab-paclitaxel	4	2
Gemcitabine + cabecitabine	11	6
Gemcitabine + investigational drugc	9	5
Gemcitabine + erlotinib	2	1
GTX (gemcitabine, docetaxel, capecitabine)	6	3
FOLFIRINOX (5-FU, irinotecan, oxaliplatin)	59	33
FOLFOX (5-FU, leucovorin, oxaliplatin)	13	7
No chemotherapy received	11	6
Lines of treatment received
One	169	94
Two	122	68
Three	81	45
Four	30	17
Five	4	2

Abbreviations: AJCC = American Joint Committee on Cancer; NA = not available; ULN = upper limit of normal.

^aDistal pancreatectomy w/wo splenectomy, Appleby procedure.

^bNot all patients have the Lewis antigen and therefore cannot secrete CA19-9.

^cInvestigational drugs: olaparib (PARP inhibitor), vismodegib (Hedgehog Pathway Inhibitor), clivatuzumab (y90 + h-PAMA4 fractionated radioimmunotherapy), nivolomab (IgG4 anti-PD-1 monoclonal antibody), BKM-120 (PI3K inhibitor), veliparib (PARP inhibitor), ipilumumab (Cytotoxic T lymphocyte antigen 4 antibody).